GLP-1 Makers Sued Over Rare Sudden Vision Loss
Thousands of patients say the companies failed to warn them about a rare eye stroke linked to sudden, sometimes permanent vision loss.
- Dozens of patients have filed Lawsuits against drugmakers Novo and Eli Lilly, alleging the companies failed to warn users about sudden vision loss from GLP-1s including Ozempic, Wegovy, Mounjaro, and Zepbound.
- Non-Arteritic anterior ischaemic optic neuropathy, or NAION, is a rare condition that can lead to sudden and sometimes permanent vision loss due to lack of blood flow to the optic nerve.
- Research involving more than 159,000 participants with type 2 diabetes found 35 cases of NAION among GLP-1 users compared to 19 in the comparison group; researchers also identified 93 patients with 'Other optic nerve disorders.'
- Similar Lawsuits against Eli Lilly are currently pending, with plaintiffs claiming the company failed to adequately warn patients of risks associated with their weight-loss and diabetes treatments.
- The American Academy of Ophthalmology encourages clinicians and patients to make 'informed choices' regarding GLP-1s, while noting that studies show modest risk but fewer patients experienced sight-threatening complications from diabetes.
86 Articles
86 Articles
Ozempic, Wegovy and Mounjaro face US lawsuits over rare vision-loss risk
Dozens of people in the United States have sued the manufacturers of popular GLP-1 drugs, claiming that the medicines caused a rare eye condition that can result in permanent vision loss, according to US media reports.
Ozempic, Mounjaro face lawsuits in the US over vision loss. What's the risk?
US lawsuits have put a spotlight on claims that GLP-1 drugs may be linked to the rare eye condition NAION. Doctors say the evidence remains mixed, with no reported cases in India so far and the risk still under investigation.
What GLP-1 users should know about the potential risk of a rare type of vision loss - Regional Media News
Dozens of Americans have filed personal injury lawsuits against the makers of popular GLP-1 drugs, like Ozempic, Wegovy and Mounjaro, claiming they were not properly warned of the risk of a rare type of sudden vision loss, called nonarteritic anterior ischemic optic neuropathy, or NAION, [...]
Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
The lawsuits said the drugmakers should have known about and informed patients of the potential for this side effect, which is not included on the warning labels for the medications.
TVA Nouvelles
24 heuresHundreds of lawsuits have been brought in the past 12 months in the United States against manufacturers of GLP-1 drugs.
Coverage Details
Bias Distribution
- 71% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
